Proteomics Research of Osteosarcoma
- Conditions
- ProteomicsOsteosarcoma
- Interventions
- Drug: Chemotherapy
- Registration Number
- NCT03932058
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Brief Summary
Retrospectively collected 400 cases of clinical data and pathological paraffin specimens of osteosarcoma, chondrosarcoma (control) and endogenous chondroma (control) in our hospital from 2008 to 2014, combined with high-pressure cycle-satellite scanning mass spectrometry (PCT-SWATH) Molecular typing of osteosarcoma and prediction of targeted therapy, the establishment of a new molecular classification based on proteomics for osteosarcoma to predict the chemotherapy response and recurrence risk of osteosarcoma. Clinical osteosarcoma patients include as many types as possible: pre-chemotherapy, post-chemotherapy, recurrence, and metastasis. The study did not involve vulnerable groups, and it was taken as a postoperative wax specimen for patients, which had no health, life and other effects on patients. Study application exemption from informed consent.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 400
- all osteosarcoma patients in our hospital
- received Methotrexate+Doxorubicin+Cisplatin protocol chemotherapy
- non-chemotherapy patients
- bio-specimen not completed
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description osteosarcoma Chemotherapy -
- Primary Outcome Measures
Name Time Method proteomics changes 2 years Study of changes in proteomes in tumor cells by high-throughput proteomics analysis
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
2nd Affiliated Hospital of Zhejiang University
🇨🇳Hangzhou, Zhejiang, China